Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $120 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Olivia Brayer has reiterated an Overweight rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and maintained a price target of $120.
August 01, 2023 | 2:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biomarin Pharmaceutical's stock rating has been reiterated as Overweight by Cantor Fitzgerald, with a maintained price target of $120.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Biomarin Pharmaceutical. The maintained price target of $120 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100